Hemispherian Raises Seed Funding For Novel Cancer Therapeutics
05/03/22, 3:00 AM
Location
osloRound Type
seed
Hemispherian AS ("Hemispherian" or the "Company"), a Norwegian preclinical pharmaceutical company focused on small molecule cancer therapeutics targeting the DNA damage response, is delighted to announce the closure of its successful seed financing. The oversubscribed round raised NOK 12.5M (USD 1.4M). The proceeds will support the company's drug development activities, expand its preclinical pipeline and move its lead therapeutic compounds towards clinical development.
Company Info
Location
oslo, oslo, norway
Additional Info
Hemispherian is an innovative pharmaceutical company focused on developing a novel class of small molecule drugs (GLIX). GLIX compounds target the TET2 enzyme and activate the DNA damage response resulting in cancer cell death. The company's lead compound, GLIX1, is in late-stage preclinical development for the treatment of glioblastoma multiforme, a deadly cancer of the central nervous system and the leading cause of death by disease in children. Hemispherian is further focused on developing a companion diagnostic tool to support patient selection for optimal therapeutic response to GLIX1. Hemispherian is based in Oslo, Norway. For more information, visit www.hemispherian.com.